Publications
118
Citations
1,092
Est. group size
~2
Recurring co-author estimate
Active years
22
Publishing since 2005
Urs von Holzen conducts laboratory-based cancer research focused on gastrointestinal malignancies, particularly esophageal adenocarcinoma (cancer of the food pipe), pancreatic cancer, and related digestive-system tumors. The work centers on testing molecular-targeted drugs and drug combinations—such as inhibitors of specific proteins involved in tumor growth and metabolism—to improve treatment responses in experimental models. Studies typically combine cell and tissue analysis with preclinical evaluation of candidate therapies.
Publication output has been fairly steady across the decade with year-to-year fluctuation, peaking around 2023 and averaging roughly 8 papers per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~7 · 8% small-team papers (≤3 authors) · across 44 venues
- Abstract 401: Targeting Hsp90β potentiates nab-paclitaxel-based chemotherapy response in pancreatic cancer models.
Cancer Research · 2026
- Abstract 295: Antitumor effect of a new pyruvate kinase M2 (PKM2) inhibitor Acyclovir in experimental esophageal adenocarcinoma.
Cancer Research · 2026
- Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1
International Journal of Molecular Sciences · 2025
- Abstract 5640: The KRASG12Dinhibitor MRTX1133 demonstrates significant antitumor activity and enhances nanoparticle-paclitaxel chemotherapy outcomes in pancreatic cancer
Cancer Research · 2025
- Transcriptomic profiling of laser-capture microdissected FFPE esophageal tissues identifies key drivers of esophageal adenocarcinoma
SSRN Electronic Journal · 2025
- Abstract 3080: PKM2 inhibition overcomes lapatinib resistance in HER2 overexpressing esophageal adenocarcinoma
Cancer Research · 2025
- Abstract 3035: Effects of novel isoform selective HSP90 beta inhibitors alone and in combinations against experimental esophageal adenocarcinoma
Cancer Research · 2025
- Potent antitumor activity of the KRAS G12D inhibitor MRTX1133 in pancreatic cancer: Augmenting the nanoparticle-paclitaxel chemotherapy response.
Journal of Clinical Oncology · 2025
- Synergistic Disruption of Survival and Metastatic Potential in Esophageal Adenocarcinoma Cells Through Combined Inhibition of HIF1α and CD73
Preprints.org · 2025
- Inhibition of Insulin-like Growth Factor 1 Receptor/Insulin Receptor Signaling by Small-Molecule Inhibitor BMS-754807 Leads to Improved Survival in Experimental Esophageal Adenocarcinoma
Cancers · 2024
- TRIM31: A Protein With an Oncogenic Role in Esophageal Adenocarcinoma
Proceedings of IMPRS · 2024
- Abstract 555: Role of TRIM31 in the pathogenesis of esophageal adenocarcinoma
Cancer Research · 2024
- Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)
Oncology Reports · 2023
- Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
Biomedicines · 2023
- Mediastinal Intrathymic Parathyroid Adenoma: A Case Report and Review of the Literature
Cureus · 2023
- Cancer Research×24
- PMC×3
- Experimental and Molecular Therapeutics×3
- BMC Cancer×2
- Scientific Reports×2
- Md Sazzad Hassan
Medicine · Indiana University
- Chengyuan Fang
Medicine · University of Michigan
- Joel H. Rubenstein
Medicine · University of Michigan
- Henry D. Appelman
Medicine · University of Michigan
- Peng Zhang
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile